We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Inform Genomics and TD2 Announce Strategic Collaboration
News

Inform Genomics and TD2 Announce Strategic Collaboration

Inform Genomics and TD2 Announce Strategic Collaboration
News

Inform Genomics and TD2 Announce Strategic Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Inform Genomics and TD2 Announce Strategic Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Inform Genomics, Inc. and Translational Drug Development LLC (TD2) have announced a strategic collaboration leveraging Inform Genomics’ proprietary technology platform and analytic capabilities to biopharmaceutical companies through TD2’s oncology drug development services.

"We are very pleased to establish this strategic collaboration with TD2, as we see significant synergies between Inform Genomics’ proprietary technology and analytics along with TD2’s world-class oncology drug development service,” said Ed Rubenstein, MD, President and CEO of Inform Genomics.

Rubenstein continued, “Developing predictive genomic-based networks of side effects of early product candidates may help identify subpopulations at risk during later stages of clinical trials.”

"TD2's focus on precision oncology solutions, coupled with Inform Genomics ability to understand individual patient risk for side effects, can give a more complete vision of personalized medicine that has the opportunity to significantly improve patient care,” said Stephen Gately, PhD, President and CEO of TD2.

“Having a technology to determine who will or will not develop specific types of toxicities with a particular therapy or a new agent presents a much needed new aspect of personalized medicine,” said Daniel D. Von Hoff, MD, FACP, and Chief Development Officer of TD2.

Advertisement